Who
John Aballi
President and CEO
Company insider
Files Form 4 as: President and CEO, Exagen.
In numbers
- Trades disclosed
- 23
- Buys
- 3
- Sells
- 5
- Bought
- $387K
- Sold
- $901K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Oct 2022
- Last trade
- 16 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 19 Oct 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $270K34,294 at $7.87 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $316K100,000 at $3.16 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $316K100,000 at $3.16 | filing |
| 12 Mar 2026filed 16 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $57K15,698 at $3.62 | filing |
| 3 Mar 2026filed 4 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $7,8002,535 at $3.08 | filing |
| 3 Mar 2026filed 4 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $57K15,698 at $3.62 | filing |
| 3 Mar 2026filed 4 Mar 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $7,8082,535 at $3.08 | filing |
| 24 Feb 2026filed 25 Feb 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $41K11,430 at $3.61 | filing |
| 24 Feb 2026filed 25 Feb 2026 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $41K11,430 at $3.61 | filing |
| 16 Oct 2025filed 20 Oct 2025 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $376K31,787 at $11.82 | filing |
| 28 Feb 2025filed 4 Mar 2025 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $21K8,621 at $2.47 | filing |
| 21 Feb 2025filed 25 Feb 2025 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | $269K75,000 at $3.58 | filing |
| 21 Feb 2025filed 25 Feb 2025 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 14 Nov 2024filed 18 Nov 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Bought | $68K24,305 at $2.81 | filing |
| 16 May 2024filed 16 May 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Bought | $78K40,401 at $1.92 | filing |
| 29 Feb 2024filed 4 Mar 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | $19K9,804 at $1.91 | filing |
| 20 Feb 2024filed 22 Feb 2024 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 17 Oct 2023filed 18 Oct 2023 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Sold | $59K33,819 at $1.75 | filing |
News
Canaccord Genuity Group Issues Positive Forecast for Exagen (NASDAQ:XGN) Stock PriceXGN · themarketsdaily.com · 19 Oct 2026Centene (NYSE:CNC) vs. Exagen (NASDAQ:XGN) Head to Head SurveyXGN · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name John Aballi; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.